TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802008

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-minute withdrawal time
Description: For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute withdrawal time
Description: For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist.
Study: NCT01900795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 4.5 mg suspension taken orally after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg tablets taken orally after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally after surgery.
Study: NCT02537249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
Study: NCT04838535

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Raman spectrum
Description: The wavelength of the follicular fluids were scaned by Raman spectrum
Study: NCT00940940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax (Live attenuated herpes zoster vaccine)
Description: 0.6 mL subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: 0.65 mL subcutaneous
Study: NCT01938326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approach Method
Description: SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approach Method
Description: SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
Study: NCT01943604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutella Breakfast
Description: Breakfast composed of bread and Nutella, milk and apple slices
Study: NCT01683799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: 6-week behavioral treatment for insomnia
Study: NCT04256824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coated vicryl plus
Description: Coated Polyglactin 910 with Triclosan (coated vicryl plus)
Study: NCT01943604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waffle Breakfast
Description: Breakfast composed of waffles and syrup, milk, and apple slices
Study: NCT02404142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curare (Atracurium)
Description: Curare (Atracurium) versus saline isotonic solution for tracheal intubation
Study: NCT04256824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: Coated Polyglactin 910 without Triclosan (vicryl)
Study: NCT03854058

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic phrenic nerve stimulation
Description: cervical and cortical stimulation of N. Vagus
Study: NCT02404142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline isotonic solution
Study: NCT01634776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Description: Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Study: NCT03488836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reciproc
Description: rotary reciprocating protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: race rotary
Description: race rotary group protocol
Study: NCT00722020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Description: 15 minutes of HFCWO via the Vest 2-3 times daily
Study: NCT00764218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment
Description: Positive airway pressure treatment as long as necessary

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment
Description: Positive airway pressure treatment as long as necessary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No positive airway pressure treatment
Description: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No positive airway pressure treatment
Description: No treatment
Study: NCT00477685

Intervention type: DEVICE
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
Study: NCT01883167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Description: RDEA3170 10 mg once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Description: RDEA3170 10 mg once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo qd
Study: NCT03451045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: Subjects will receive lenabasum 20 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: Subjects will receive lenabasum 5 mg twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo twice daily.
Study: NCT04388423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated puncture training
Description: The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional bedside teaching
Description: The residents are trained by traditional bedside teaching
Study: NCT01781247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal behavioral intervention
Description: The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided.
Study: NCT02020642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Description: Renal transplantation from cadaveric or live donor
Study: NCT01518062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
Study: NCT03661775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate administration
Description: controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate administration
Description: controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
Study: NCT00374868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
Study: NCT04751266

Intervention type: PROCEDURE
Intervention: minimally invasive repair of pectus excavatum
Description: substernal insertion of a metal bar
Study: NCT00614679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
Description: N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
Study: NCT02726620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attending real-time decision support
Description: Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-room real-time decision support
Description: Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
Study: NCT00166699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: The use of ultrasound to guide the insertion of combined spinal epidural needle
Study: NCT02722967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole + IEM (Ingestible Event Marker)
Description: Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
Study: NCT01508000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6
Description: 5-FU, folinic acid, oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: 5-FU, folinic acid, oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: 5-FU, folinic acid, oxaliplatin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Targeted therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Targeted therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT02726620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attending feedback emails
Description: Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-room provider feedback emails
Description: In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Information Management System (AIMS)
Description: The anesthesia electronic record keeping system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative Data Warehouse (PDW)
Description: The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
Study: NCT02062593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronary angioplasty
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques
Study: NCT02708329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-provisional stenting
Description: Standard endovascular T-provisional stenting technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-crush stenting
Description: Standard endovascular Mini-crush stenting technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study: NCT00591721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy conservation education
Description: The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Energy conservation education
Description: The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
Study: NCT02279628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
Study: NCT02726620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
Study: NCT02279628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
Study: NCT04403464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE with REAtouch®
Description: 65h HABIT-ILE including 30h REAtouch®

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HABIT-ILE without REAtouch®
Description: 65h HABIT-ILE
Study: NCT02726620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pager system
Description: The mobile pager system through which alerts can be sent
Study: NCT01508000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT03410316

Intervention type: OTHER
Intervention: No intervention
Study: NCT03776045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus exercise
Description: The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted \~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
Study: NCT02138383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
Study: NCT03514953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Physical Activity
Description: Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns.